drugset / Trial / NCT05223686
To Evaluate the Safety and Tolerability of Human CD19-CD22 Targeted T Cells Injection for Subjects With R/R B-ALL.
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the safety and tolerability of Human CD19-CD22 Targeted T Cells Injection for the treatment of Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia. Patients will be given a conditioning chemotherapy regimen of fludarabine and cyclophosphamide followed by a single infusion of CD19-CD22 CAR+ T cells.
Timeline
- Start
- 2022-02-10
- Primary completion
- 2023-06-10
- Completion
- 2025-03-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Human CD19-CD22 Targeted T Cells Injection | Cell therapy | 1e+06 cells | — |
| Subject | Human CD19-CD22 Targeted T Cells Injection | Cell therapy | 3e+06 cells | — |
| Subject | Human CD19-CD22 Targeted T Cells Injection | Cell therapy | 6e+06 cells | — |